Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik S G Stroes

Showing results (1-10 of 381) with videos related to

Pageof 39
Sort By:
The American Journal of Cardiology|November 10, 2009
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitorsMenno Vergeer, Erik S G Stroes
Atherosclerosis|April 3, 2020
The dedicated "Lp(a) clinic": A concept whose time has arrived?Sotirios Tsimikas, Erik S G Stroes
Current Opinion in Lipidology|September 23, 2016
HDL infusion for the management of atherosclerosis: current developments and new directionsKang H Zheng, Erik S G Stroes
JACC. Basic to Translational Science|June 16, 2023
Inflammatory Effects of Triglycerides: Relevant or Redundant?Jordan M Kraaijenhof, Erik S G Stroes
Current Opinion in Lipidology|October 17, 2017
The shape of things to come in lipid management: a feast of reasonGerald F Watts, Erik S G Stroes
Lancet (London, England)|March 17, 2012
The interleukin-6 pathway and atherosclerosisS Matthijs Boekholdt, Erik S G Stroes
NEJM Evidence|February 6, 2024
Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?Jordan M Kraaijenhof, Erik S G Stroes
Arthritis and Rheumatism|May 29, 2007
Mannose-binding lectin and agalactosyl IgG and risk of ischemic heart disease in rheumatoid arthritis: comment on the article by Troelsen et alSander I van Leuven, Erik S G Stroes
Nature Reviews. Cardiology|March 25, 2026
ApoC-III inhibition: from regulatory approval to equitable implementationDaniel Gaudet, Miriam Larouche, Erik S G Stroes
The New England Journal of Medicine|November 17, 2018
FISHing for the Miracle of Eicosapentaenoic AcidJohn J P Kastelein, Erik S G Stroes
Pageof 39

Showing results (1-10 of 381) with videos related to

Sort By:
Pageof 39
The American Journal of Cardiology|November 10, 2009
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitorsMenno Vergeer, Erik S G Stroes
Atherosclerosis|April 3, 2020
The dedicated "Lp(a) clinic": A concept whose time has arrived?Sotirios Tsimikas, Erik S G Stroes
Current Opinion in Lipidology|September 23, 2016
HDL infusion for the management of atherosclerosis: current developments and new directionsKang H Zheng, Erik S G Stroes
JACC. Basic to Translational Science|June 16, 2023
Inflammatory Effects of Triglycerides: Relevant or Redundant?Jordan M Kraaijenhof, Erik S G Stroes
Current Opinion in Lipidology|October 17, 2017
The shape of things to come in lipid management: a feast of reasonGerald F Watts, Erik S G Stroes
Lancet (London, England)|March 17, 2012
The interleukin-6 pathway and atherosclerosisS Matthijs Boekholdt, Erik S G Stroes
NEJM Evidence|February 6, 2024
Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?Jordan M Kraaijenhof, Erik S G Stroes
Arthritis and Rheumatism|May 29, 2007
Mannose-binding lectin and agalactosyl IgG and risk of ischemic heart disease in rheumatoid arthritis: comment on the article by Troelsen et alSander I van Leuven, Erik S G Stroes
Nature Reviews. Cardiology|March 25, 2026
ApoC-III inhibition: from regulatory approval to equitable implementationDaniel Gaudet, Miriam Larouche, Erik S G Stroes
The New England Journal of Medicine|November 17, 2018
FISHing for the Miracle of Eicosapentaenoic AcidJohn J P Kastelein, Erik S G Stroes
Pageof 39